EULAR 2019: Lilly's Taltz bests Humira in PsA

US pharma major Eli Lilly (NYSE: LLY) presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s (NYSE: ABBV) Humira (adalimumab) in active psoriatic arthritis (PsA).

The primary endpoint of the study was superiority for Taltz in the proportion of patients who simultaneously achieved a reduction by at least 50% in disease activity, and complete skin clearance for psoriasis.

At 24 weeks, the proportion of patients achieving a reduction in both measures was significantly higher for Taltz, at 36% compared to Humira’s 28%.